Ascendis Pharma Past Earnings Performance
Past criteria checks 0/6
Ascendis Pharma's earnings have been declining at an average annual rate of -15%, while the Biotechs industry saw earnings growing at 12.6% annually. Revenues have been growing at an average rate of 73.3% per year.
Key information
-15.0%
Earnings growth rate
-11.6%
EPS growth rate
Biotechs Industry Growth | 12.9% |
Revenue growth rate | 73.3% |
Return on equity | n/a |
Net Margin | -130.3% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Ascendis Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 327 | -426 | 275 | 319 |
30 Jun 24 | 318 | -490 | 269 | 356 |
31 Mar 24 | 329 | -502 | 265 | 378 |
31 Dec 23 | 267 | -481 | 264 | 413 |
30 Sep 23 | 152 | -602 | 257 | 431 |
30 Jun 23 | 119 | -609 | 254 | 417 |
31 Mar 23 | 78 | -569 | 240 | 403 |
31 Dec 22 | 51 | -583 | 221 | 380 |
30 Sep 22 | 33 | -482 | 213 | 337 |
30 Jun 22 | 19 | -393 | 192 | 298 |
31 Mar 22 | 14 | -446 | 170 | 291 |
31 Dec 21 | 8 | -384 | 160 | 296 |
30 Sep 21 | 3 | -416 | 132 | 491 |
30 Jun 21 | 5 | -458 | 111 | 432 |
31 Mar 21 | 5 | -418 | 96 | 349 |
31 Dec 20 | 7 | -419 | 77 | 261 |
30 Sep 20 | 9 | -360 | 73 | 50 |
30 Jun 20 | 8 | -264 | 66 | 192 |
31 Mar 20 | 10 | -228 | 56 | 140 |
31 Dec 19 | 13 | -218 | 48 | 192 |
30 Sep 19 | 21 | -170 | 40 | 179 |
30 Jun 19 | 19 | -178 | 37 | 70 |
31 Mar 19 | 16 | -142 | 31 | 161 |
31 Dec 18 | 11 | -130 | 25 | 140 |
30 Sep 18 | 0 | -132 | 21 | 130 |
30 Jun 18 | 1 | -132 | 17 | 128 |
31 Mar 18 | 1 | -140 | 15 | 110 |
31 Dec 17 | 2 | -124 | 13 | 100 |
30 Sep 17 | 2 | -106 | 13 | 92 |
30 Jun 17 | 3 | -91 | 12 | 79 |
31 Mar 17 | 4 | -73 | 12 | 70 |
31 Dec 16 | 5 | -69 | 12 | 66 |
30 Sep 16 | 6 | -64 | 12 | 59 |
30 Jun 16 | 6 | -53 | 10 | 50 |
31 Mar 16 | 7 | -55 | 10 | 49 |
31 Dec 15 | 8 | -33 | 9 | 41 |
30 Sep 15 | 9 | -26 | 8 | 36 |
30 Jun 15 | 10 | -21 | 8 | 31 |
31 Mar 15 | 12 | -8 | 8 | 23 |
31 Dec 14 | 14 | -10 | 6 | 20 |
30 Sep 14 | 17 | -2 | 4 | 15 |
30 Jun 14 | 20 | 0 | 3 | 15 |
31 Mar 14 | 20 | 3 | 3 | 13 |
31 Dec 13 | 20 | 4 | 2 | 13 |
Quality Earnings: ASND N is currently unprofitable.
Growing Profit Margin: ASND N is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ASND N is unprofitable, and losses have increased over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare ASND N's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ASND N is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (2.6%).
Return on Equity
High ROE: ASND N's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.